Clinical Trials in San Diego

Showing 2081-2100 of 7,028 trials

TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3)

NCT05862324

TAC01-CLDN18.2 is a novel cell therapy that consists of genetically engineered autologous T cells expressing T-cell Antigen Coupler (TAC) that recognizes Claudin 18.2. TAC directs T-cells to the targeted antigen (CLDN 18.2), and once engaged with the target, activates them via the endogenous T cell receptor. This is an open-label, multicenter Phase ½ study that aims to establish safety, maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D), pharmacokinetic profile and efficacy of TAC01-CLDN18.2.

Metastatic Solid Tumor

Triumvira Immunologics, Inc.113 participantsStarted Aug 2023

Los Angeles, California, United States • San Diego, California, United States • Miami, Florida, United States +6 more locations

COMPLETEDPhase 3< 1 mile

Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.

NCT02437318

To determine whether treatment with alpelisib plus fulvestrant prolonged progression-free survival (PFS) compared to fulvestrant and placebo in men and postmenopausal women with hormone receptor positive (HR+), human epidermal growth factor receptor-2 (HER2)-negative advanced breast cancer, who received prior treatment with an aromatase Inhibitor (AI) either as (neo)adjuvant or for advanced disease.

Breast Cancer

Novartis Pharmaceuticals572 participantsStarted Jul 2015

Chandler, Arizona, United States • Scottsdale, Arizona, United States • Fayetteville, Arkansas, United States +194 more locations

TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3)

Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.

Find Trials by Condition in San Diego

ATHN 7: Hemophilia Natural History Study

Artoss Prospective Spine Registry Outcomes

Real-Time Levodopa Level Monitoring in Parkinson Disease

Open-Label Study of Setmelanotide in Hypothalamic Obesity

Microbiome, Atopic Disease, Prematurity

Repigmentation of Stable Vitiligo Lesions Using Spray-On Skin™ Cells

Phase 2b Safety and Efficacy Study of CGB-500 Topical Ointment with 0.5% and 1% Tofacitnib for Treatment of Atopic Dermatitis

Different Doses of Naronapride Vs. Placebo in Gastroparesis

Non-comparative Study of IFX-1 Alone or IFX-1+Pembrolizumab in Patients With Locally Advanced or Metastatic cSCC.

A Phase 2b Study of BNC210 Tablet Formulation in Adults With Post-Traumatic Stress Disorder (PTSD)

Evaluation of Lasofoxifene Combined With Abemaciclib in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies

Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)

Myeloma-Developing Regimens Using Genomics (MyDRUG)

(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations

Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements

COVID-19 Vaccine Response in Sickle Cell Disease

Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer